The Michael J. Fox Foundation Grants Second Award to NeuroHealing for Clinical Trial of NH004 for Sialorrhea Control in Parkinson’s Disease

Newton, Massachusetts – August 26, 2011. NeuroHealing Pharmaceuticals, a private, clinical stage company developing drug treatments for individuals with neuro-rehabilitation needs, announced today that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded the company a grant to advance the clinical development of NH004, a novel treatment for sialorrhea (uncontrolled drooling). This grant…

NeuroHealing Announces Orphan Drug Designation in Europe for NH001 for the Treatment of Patients Following a Moderate or Severe Traumatic Brain Injury

Provides a 10-Year Regulatory Exclusivity for the European Community Newton, Massachusetts – May 23, 2011. NeuroHealing Pharmaceuticals today announced that the European Commission has granted Orphan Drug Designation EU/3/11/862 for NH001 for the treatment of patients following a moderate or severe traumatic brain injury (TBI). The designation follows a positive opinion from the Committee for…

NeuroHealing Announces Strategic Master Services and Investment Agreement with Cato BioVentures

Newton, Massachusetts – May 16, 2011. NeuroHealing Pharmaceuticals today announced that it has entered into a strategic master services and investment agreement with Cato BioVentures. This agreement includes a collaboration with Cato Research Ltd. (“Cato”), its global contract research organization, to assist in the clinical development of NeuroHealing’s lead drug NH001. The investment and collaboration…

NeuroHealing Announces Issuance of U.S. Patent for Brain Injury Treatment

Newton, Massachusetts – May 9, 2011. NeuroHealing Pharmaceuticals announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application 11/240,281 entitled “High Potency Dopaminergic Treatment of Neurological Impairment Associated with Brain Injury.” U.S. Patent 7,943,632 will issue May 17, 2011. The patent claims cover methods and…

Positive Results of Phase II Clinical Study for the Treatment of Sialorrhea Presented at Parkinson’s Disease Congress

Newton, Massachusetts – December 10, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the presentation of clinical trial results with NH004 for the treatment of sialorrhea (uncontrolled drooling) in Parkinson’s disease patients. The presentation today at the International Congress on Mental…

NeuroHealing Awarded Qualified Therapeutic Development Project Grant

Grant Supports Development of NH001 for the Treatment of Patients in a Coma, Vegetative State or Minimally Conscious State Following a Traumatic Brain Injury Newton, Massachusetts – November 3, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, today announced that it has…

NeuroHealing Receives Notice of Allowance from the U.S. Patent and Trademark Office for a New Treatment for Premature Ejaculation

Newton, Massachusetts – October 13, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance for a patent entitled “Modafinil-based Treatment for Premature Ejaculation.” The patent (US…

NeuroHealing Pharmaceuticals Announces Publication Supporting the Use of NH001 to Treat Patients in a Coma and Issuance of NH001 Patent

Article published in April 2010 issue of Brain Injury Newton, Massachusetts – April 14, 2010. NeuroHealing Pharmaceuticals, a private, clinical stage company developing innovative drug treatments for specialty indications based on repositioning neurologically active compounds, announces the publication of a scientific article in the journal Brain Injury, supporting the use and further development of NH001…